Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR mutant non-small cell lung cancer (NSCLC) is limited by the development of drug resistance mutations, including the gatekeeper T790M mutation1-3. Strategies aimed at targeting EGFR T790M with irreversible inhi...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
मुख्य लेखकों: Zhou, Wenjun, Ercan, Dalia, Chen, Liang, Yun, Cai-hong, Li, Danan, Capelletti, Marzia, Cortot, Alexis B., Chirieac, Lucian, Iacob, Roxana E., Padera, Robert, Engen, John R., Wong, Kwok-Kin, Eck, Michael J., Gray, Nathanael S., Jänne, Pasi A.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2009
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC2879581/
https://ncbi.nlm.nih.gov/pubmed/20033049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature08622
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन